Clinical trials: Blood Transfusion Complication
Transfusion Reaction
Clinical Performance Study of Safety Test ABO Device
The study aims to confirm the performance equivalence of the in vitro diagnostic device Safety Test ABO with the ABTest Card device.
- Trial name
- NCT06543771
- Testing
- Safety Test ABO and ABTest Card®
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Diagast
Blood Loss, Surgical, Postoperative Hemorrhage
Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery
The objective of this study is to evaluate the safety and efficacy of aprotinin as compared to placebo, in reducing the need for blood transfusion in adult subjects undergoing elective spinal fusion surgery involving 3 to 7…
- Trial name
- NCT00327379
- Testing
- Trasylol (Aprotinin, BAYA0128)
- Where
- 14 sites in Canada, Germany and 1 more
- Volunteers
- 54 people
- Sponsor
- Bayer
Anemia, Blood Loss, Surgical
An Observational Study of Blood Management Techniques in Oncology Surgical Treatment
The purpose of this study is to observe the methods used to manage blood loss in surgical procedures to remove tumors from patients with cancer and to determine if there is a relationship with the need for blood transfusions.
- Conditions
- Anemia, Blood Loss, Surgical, Neoplasms
- Trial name
- NCT00264095
- Testing
- Oncological surgery
- Where
- 11 sites in Netherlands
- Volunteers
- 488 people
- Sponsor
- Janssen-Cilag B.V.
Transfusion Reaction
ABTEST© Card Clinical Perfomance Study
The study confirms the performance equivalence of the in vitro Diagnostic reagent ABTEST card used with the new reformulated WS solution
- Trial name
- NCT05140395
- Testing
- ABTEST card
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Diagast
Transfusion Reaction
Clinical Performance Study of the ABTest Card® Device.
The study aims to confirm the performance equivalence of the in vitro diagnostic device ABTest Card®REF with the ABTest Card®NEW device.
- Trial name
- NCT06557031
- Testing
- ABTest Card®REF and ABTest Card®NEW
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Diagast
Anemia, Multiple Myeloma
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa versus placebo in reducing or preventing the need for transfusions in anemic patients with cancer receiving chemotherapy, and to investigate…
- Conditions
- Anemia, Multiple Myeloma, Lymphoma, Breast Cancer
- Trial name
- NCT00270166
- Testing
- epoetin alfa
- Volunteers
- 201 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Severe Postpartum Haemorrhage
Treatment of Women After Severe Postpartum Haemorrhage
The primary purpose of this study is to get explorative information about IV high single dose infusion of iron isomaltoside 1000 compared to RBC transfusion in the treatment of severe PP-IDA evaluated as physical fatigue
- Trial name
- PP-02 (NCT01895205)
- Testing
- Iron isomaltoside 1000, Red blood cell transfusion
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Pharmacosmos A/S
Blood Loss, Surgical
Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement
The purpose of this study is to assess if aprotinin (BAY A0128), given intravenously during surgery, is safe and can help reduce the amount of bleeding and the need for a blood transfusion during hip replacement surgery.
- Trial name
- NCT00668031
- Testing
- Trasylol (Aprotinin, BAYA0128)
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 359 people
- Sponsor
- Bayer
Transfusion Reaction, Hemolytic
Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs
This study aims to determine whether transfusion of INTERCEPT RBCs into patients with pre-existing antibodies to INTERCEPT RBCs will result in increased antibody titer indicative of a secondary immune response, and whether these…
- Trial name
- Challenge (NCT07152379)
- Testing
- 30-40 mL of INTERCEPT RBCs, ~30 mL of INTERCEPT RBCs plus plus 10 mL biotinylated INTERCEPT RBCs
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Cerus Corporation
Post Operative Hemorrhage, Transfusion Related Complication
Monitoring Noninvasively for Infusion and Transfusion Optimization
This is a multicenter, cluster randomized controlled trial to assess the effects of an optimized intraoperative fluid and blood management strategy on postoperative complications.
- Conditions
- Post Operative Hemorrhage, Transfusion Related Complication, Blood Transfusion Associated Adverse Reactions, Hypovolemia
- Trial name
- NCT04388722
- Testing
- Pulse CO-Oximeter Sensor
- Sponsor
- Masimo Corporation
Blood Loss, Surgical
Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer
Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer.
- Trial name
- NCT00306137
- Testing
- Trasylol (Aprotinin, BAYA0128)
- Where
- 21 sites in United States, Australia and 8 more
- Volunteers
- 104 people
- Sponsor
- Bayer
Renal Insufficiency, Chronic, Anemia
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
The purpose of this study is to compare two different dosing methods of epoetin alfa and their effectiveness in maintaining hemoglobin levels between 10.0 to 11.0 g/dL in in patients with chronic kidney disease (CKD) receiving…
- Conditions
- Renal Insufficiency, Chronic, Anemia, Renal Dialysis, Erythrocyte Transfusion
- Trial name
- NCT02253654
- Testing
- Epoetin alfa
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 216 people
- Sponsor
- Amgen
Blood Loss, Surgical, Postoperative Hemorrhage
Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy
The purpose of this study is to assess if aprotinin (BAYA0128), given intravenously during your surgery, is safe and can help reduce the need for a blood transfusion during bladder surgery.
- Trial name
- NCT00306150
- Testing
- Trasylol (Aprotinin, BAYA0128)
- Where
- 37 sites in United States, Belgium and 5 more
- Volunteers
- 57 people
- Sponsor
- Bayer
Transfusion Related Acute Lung Injury
A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components
This study is a prospective, non-randomized sequential cohort, open label, multi-center, non-inferiority, Phase IV surveillance study following transfusion of INTERCEPT PCs.
- Trial name
- PIPER (NCT02549222)
- Testing
- Standard of Care
- Where
- 15 sites in United States
- Volunteers
- 2,291 people
- Sponsor
- Cerus Corporation
Postoperative Hemorrhage
Aprotinin US Special Access Protocol
This is a special access protocol that will allow physicians access to aprotinin during the temporary marketing suspension. The program will provide aprotinin for treatment of surgical patients undergoing coronary artery bypass…
- Trial name
- NCT00611845
- Testing
- Aprotinin (Trasylol, BAYA0128)
- Where
- 17 sites in United States
- Sponsor
- Bayer